CS-2239
|
|
|
- CAS号:
- 173529-10-7
- 英文名:
- HMN 176
- 英文别名:
- HMN-176;HMN 176;CS-2239;HMN 176; HMN176;(E)-4-(2-((4-Methoxyphenyl)sulfonamido)styryl)pyridine 1-oxide;Polo-like Kinase (PLK),HMN-176,HMN176,HMN 176,Inhibitor,inhibit;Benzenesulfonamide, 4-methoxy-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-;(NE)-N-[(6E)-6-[2-(1-hydroxypyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene]-4-methoxybenzenesulfonamide
- 中文名:
- CS-2239
- 中文别名:
- 化合物HMN176;HMN-176游离态;有丝分裂抑制剂(HMN-176);(E)-4-(2-((4-甲氧基苯基)磺酰胺)苯乙烯基)吡啶 1-氧化物
- CBNumber:
- CB42667261
- 分子式:
- C20H18N2O4S
- 分子量:
- 382.43
- MOL File:
- 173529-10-7.mol
|
|
|
CS-2239化学性质
-
沸点:
-
632.9±65.0 °C(Predicted)
-
|
-
密度:
-
1.24±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
under inert gas (nitrogen or Argon) at 2-8°C
-
|
-
溶解度:
-
DMSO : ≥ 30 mg/mL (78.45 mM)
-
|
-
酸度系数(pKa):
-
8.07±0.10(Predicted)
-
|
CS-2239性质、用途与生产工艺
HMN-176 是HMN-214的活性代谢物，HMN-214在小鼠异种移植瘤模型中具有有效的抗肿瘤活性。HMN-176 可通过干扰其在中心体和沿细胞骨架结构的正常亚细胞空间分布，有效地抑制 PLK-1。
HMN-176 (2.5 μM) greatly increases the duration of mitosis in hTERT-RPE1 and CFPAC-1 Cell lines. The effect of HMN-176 on spindle morphology does not appear to be related to effects on microtubule polymerization. HMN-176 (2.5, 0.25, and 0.025 μM) inhibits aster formation in a concentration dependent manner. HMN-176 (0.1, 1.0, or 10.0 µg/mL) demonstrates inhibitory effects in multiple tumors, with notable activity seen in breast, nonsmall-cell lung, and ovarian cancer specimens. HMN-176 demonstrates activity towards 63% of the breast (5/8), 67% of the non-small cell lung (4/6), and 57% of the ovarian (4/7) tumor specimens treated with 10.0 µg/mL. HMN-176 shows potent cytotoxicity, with a mean IC
50
value of 118 nM. HMN-176 displays similar cytotoxicity against tumors with various characteristics from different organs. Treatment with 3 μM HMN-176 suppresses the expression of MDR1 mRNA by 56%. HMN-176 has no significant effect on the residual promoter activity.
HMN-176 prevents spindle assembly and meiosis in Spisula oocytes by inhibiting centrosome-dependent MT nucleation, i.e., aster formation. Oocytes treated with 0.25 μM HMN-176 undergoes GVBD, but asters or spindles fails to form, even after prolonged periods. After p.o. of HMN-214 to male rats, the prodrug is not detected in the plasma, while plasma levels of HMN-176 peaks at 2 h and gradually decreases thereafter.
CS-2239
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-13647 | HMN-176 | | 1 mg | 380元 |
| 2024/01/25 | HY-13647 | CS-2239
HMN-176 | 173529-10-7 | 5mg | 1000元 |
173529-10-7, CS-2239 相关搜索:
- API
- 药靶配体
- 细胞生物学试剂
- (E)-4-(2-((4-甲氧基苯基)磺酰胺)苯乙烯基)吡啶 1-氧化物
- 化合物HMN176
- HMN-176游离态
- 有丝分裂抑制剂(HMN-176)
- 173529-10-7
- (E)-4-(2-((4-Methoxyphenyl)sulfonamido)styryl)pyridine 1-oxide
- Polo-like Kinase (PLK),HMN-176,HMN176,HMN 176,Inhibitor,inhibit
- Benzenesulfonamide, 4-methoxy-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-
- HMN 176; HMN176
- CS-2239
- (NE)-N-[(6E)-6-[2-(1-hydroxypyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene]-4-methoxybenzenesulfonamide
- HMN-176
- HMN 176